Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 616-627

  Shaheen, Mahrukh Akbar ^a   Idrees, Muhammad ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

Boceprevir; Enzyme immunoassay; Hepatitis C virus; Liver transplant; Loop mediated isothermal amplification; Nucleic acid testing; Sustained viral response; Telaprevir

Indexed keywords

EID: 84928957114     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.616     Document Type: Article

References (95)

1. Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am Fam Physician 2010; 82:1225-1229 [PMID: 21121533]
2. Kazemi B, Bandehpour M, Seyed N, Roozbehi M, Mosaffa N. Cloning and expression of hepatitis C virus core protein in pGemex-1 expression vector. Arch Iran Med 2008; 11: 173-178 [PMID: 18298295]
3. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan:a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009; 15: 5647-5653 [PMID: 19960560 DOI: 10.3748/wjg.15.5647]
4. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15:41-63 [PMID: 7597443 DOI: 10.1055/s-2007-1007262]
5. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085 DOI:10.1002/hep.20819]
6. Lin HJ, Lau JY, Lauder IJ, Shi N, Lai CL, Hollinger FB. The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. Virus Res 1993; 30: 27-41 [PMID: 7505514]
7. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30: 342-355 [PMID: 20015149 DOI: 10.1111/j.1478-3231.2009.02188]
8. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974 [PMID: 11110665 DOI: 10.1126/science.290.5498.1972]
9. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73 [PMID: 12407578]
10. Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79: 6023-6034 [PMID: 15857988 DOI: 10.1128/JVI.79.10.6023-6034.2005]
11. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702 [PMID: 9620345]
12. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961 [PMID:10365827 DOI: 10.1016/S0168-8278(99)80154-8]
13. Lok AS, Chien D, Choo QL, Chan TM, Chiu EK, Cheng IK, Houghton M, Kuo G. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497-502 [PMID: 7689528 DOI: 10.1016/0270-9139(93)90347-P]
14. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575-577 [PMID: 10655348]
15. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364 [PMID: 2496467 DOI:10.1126/science.2496467]
16. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: 350-353 [PMID: 1310478 DOI: 10.1002/ hep.1840150228]
17. Smith BD, Teshale E, Jewett A, Weinbaum CM, Neaigus A, Hagan H, Jenness SM, Melville SK, Burt R, Thiede H, Al-Tayyib A, Pannala PR, Miles IW, Oster AM, Smith A, Finlayson T, Bowles KE, Dinenno EA. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53:780-786 [PMID: 21921221 DOI: 10.1093/cid/cir499]
18. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012; 22: 156-165 [PMID: 22121001 DOI: 10.1002/rmv.717]
19. Barrera JM, Bruguera M, Ercilla MG, Sánchez-Tapias JM, Gil MP, Costa J, Gelabert A, Rodés J, Castillo R. Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers. Ann Intern Med 1991; 115:596-600 [PMID: 1909848 DOI: 10.7326/0003-4819-115-8-596]
20. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003; 7: 127-137 [PMID:12691462]
21. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: 211-218 [PMID: 12085367 DOI: 10.1053/ jhep.2002.34130]
22. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002; 12: 517-523 [PMID: 12446113 DOI: 10.1016/ S0962-8924(02)02383-8]
23. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID:10390360 DOI: 10.1126/science.285.5424.110]
24. Muerhoff AS, Jiang L, Shah DO, Gutierrez RA, Patel J, Garolis C, Kyrk CR, Leckie G, Frank A, Stewart JL, Dawson GJ. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002; 42: 349-356 [PMID: 11961241 DOI: 10.1046/j.1537-2995.2002.00052.x]
25. Azzazy HM, Mansour MM, Kazmierczak SC. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin Chem 2006; 52:1238-1246 [PMID: 16709623 DOI: 10.1373/clinchem.2006.066654]
26. Al Olaby RR, Azzazy HM. Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications. Expert Rev Mol Diagn 2011; 11: 53-64 [PMID: 21171921 DOI: 10.1586/erm.10.101]
27. Roh C, Lee HY, Kim SE, Jo SK. A highly sensitive and selective viral protein detection method based on RNA oligonucleotide nanoparticle. Int J Nanomedicine 2010; 5: 323-329 [PMID:20517476 DOI: 10.2147/IJN.S10134]
28. Shawky SM, Bald D, Azzazy HM. Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles. Clin Biochem 2010; 43: 1163-1168 [PMID: 20627095 DOI: 10.1016/ j.clinbiochem.2010.07.001]
29. Klostranec JM, Xiang Q, Farcas GA, Lee JA, Rhee A, Lafferty EI, Perrault SD, Kain KC, Chan WC. Convergence of quantum dot barcodes with microfluidics and signal processing for multiplexed high-throughput infectious disease diagnostics. Nano Lett 2007; 7:2812-2818 [PMID: 17705551 DOI: 10.1021/nl071415m]
30. Duan L, Wang Y, Li SS, Wan Z, Zhai J. Rapid and simultaneous detection of human hepatitis B virus and hepatitis C virus antibodies based on a protein chip assay using nano-gold immunological amplification and silver staining method. BMC Infect Dis 2005; 5: 53 [PMID: 15998472 DOI: 10.1186/1471-2334-5-53]
31. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000; 28: E63 [PMID: 10871386 DOI:10.1093/nar/28.12.e63]
32. Mori Y, Nagamine K, Tomita N, Notomi T. Detection of loopmediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem Biophys Res Commun 2001; 289: 150-154 [PMID: 11708792 DOI: 10.1006/ bbrc.2001.5921]
33. Nagamine K, Hase T, Notomi T. Accelerated reaction by loopmediated isothermal amplification using loop primers. Mol Cell Probes 2002; 16: 223-229 [PMID: 12144774 DOI: 10.1006/ mcpr.2002.0415]
34. Shi H, Hoffman BE, Lis JT. RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci USA 1999; 96: 10033-10038 [PMID: 10468557 DOI: 10.1073/ pnas.96.18.10033]
35. Fabrizi F, Lunghi G, Aucella F, Mangano S, Barbisoni F, Bisegna S, Vigilante D, Limido A, Martin P. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol 2005; 43: 414-420 [PMID: 15635003 DOI: 10.1128/JCM.43.1.414-420.2005]
36. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905 [PMID: 1280771 DOI: 10.1056/NEJM199212313272702]
37. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104: 8427-8432 [PMID: 17485666 DOI: 10.1073/pnas.0702162104]
38. Ahmad K. Pakistan: a cirrhotic state? Lancet 2004; 364: 1843-1844 [PMID: 15565744 DOI: 10.1016/S0140-6736(04)17458-8]
39. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013; 57 Suppl 2: S32-S38 [PMID: 23884063 DOI: 10.1093/cid/cit300]
40. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583 [PMID: 21802134 DOI:10.1016/S0140-6736(11)61097-0]
41. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57 Suppl 2: S39-S45 [PMID: 23884064 DOI:10.1093/cid/cit296]
42. Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 2013; 57 Suppl 2: S46-S50 [PMID:23884065 DOI: 10.1093/cid/cit329]
43. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
44. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36: S99-S105 [PMID: 12407582 DOI: 10.1053/ jhep.2002.36797]
45. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24: 1799-1812 [PMID:20601854 DOI: 10.1097/QAD.0b013e32833c11a5]
46. van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25: 1083-1091 [PMID:21537114 DOI: 10.1097/QAD.0b013e3283471cce]
47. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-1564 [PMID: 12447730 DOI:10.1086/345554]
48. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41 [PMID:16364080 DOI: 10.1111/j.1365-2893.2005.00651.x]
49. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83 [PMID:21628661 DOI: 10.1093/infdis/jir196]
50. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008; 46: 1852-1858 [PMID: 18462109 DOI: 10.1086/588297]
51. Pembrey L, Newell ML, Peckham C. Is there a case for hepatitis C infection screening in the antenatal period? J Med Screen 2003; 10:161-168 [PMID: 14738651 DOI: 10.1258/096914103771773230]
52. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001; 108: 371-377 [PMID: 11305543 DOI:10.1111/j.1471-0528.2001.00088.x]
53. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880-1889 [PMID: 16267758 DOI:10.1086/497701]
54. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-229 [PMID: 11481604]
55. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158: 109-113 [PMID: 23437438 DOI: 10.7326/0003-4819-158-2-201301150-00575]
56. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat 2000; 7: 93-103 [PMID: 10760039 DOI: 10.1046/j.1365-2893.2000.00203.x]
57. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61 [PMID: 15663766 DOI: 10.1111/ j.1525-139X.2005.18108.x]
58. Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58: 189-194 [PMID: 19265779]
59. Urbanus AT, van den Hoek A, Boonstra A, van Houdt R, de Bruijn LJ, Heijman T, Coutinho RA, Prins M. People with multiple tattoos and/or piercings are not at increased risk for HBV or HCV in The Netherlands. PLoS One 2011; 6: e24736 [PMID: 21935447 DOI:10.1371/journal.pone.0024736]
60. Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis 2012; 54: 1167-1178 [PMID: 22291098 DOI: 10.1093/ cid/cir991]
61. Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect 2009; 58:375-382 [PMID: 19328555 DOI: 10.1016/j.jinf.2009.02.014]
62. Samuel MC, Bulterys M, Jenison S, Doherty P. Tattoos, incarceration and hepatitis B and C among street-recruited injection drug users in New Mexico, USA: update. Epidemiol Infect 2005; 133: 1146-1148 [PMID: 16274514 DOI: 10.1017/ S0950268805225517]
63. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601 [PMID: 20637202 DOI:10.1053/j.gastro.2010.07.009]
64. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350 [PMID: 15685546 DOI:10.1053/j.gastro.2004.11.018]
65. Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198 [PMID: 20006397 DOI: 10.1016/ j.jhep.2009.11.008]
66. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4: e8209 [PMID: 19997618 DOI: 10.1371/journal.pone.0008209]
67. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.e18 [PMID: 20399780 DOI:10.1053/j.gastro.2010.04.013]
68. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
69. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441 [PMID:23669289 DOI: 10.1016/j.jhep.2013.04.035]
70. Vermehren J, Kau A, Gärtner BC, Göbel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008; 46:3880-3891 [PMID: 18799708 DOI: 10.1128/JCM.00755-08]
71. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31 [PMID: 17525931 DOI: 10.1002/ hep.21656]
72. Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, Zeuzem S. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 2010; 52: 832-838 [PMID: 20385421 DOI: 10.1016/ j.jhep.2010.01.030]
73. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
74. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]
75. Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, Tietz A, Nelson DR. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897-1903 [PMID: 20196118 DOI: 10.1002/hep.23531]
76. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134 [PMID: 17625124 DOI: 10.1056/ NEJMoa066403]
77. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960 [PMID: 16628671 DOI: 10.1002/hep.21159]
78. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-458 [PMID: 18503773 DOI: 10.1053/j.gastro.2008.04.015]
79. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609 [PMID: 12601358 DOI: 10.1053/ jhep.2003.50106]
80. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103 [PMID:16290907 DOI: 10.1016/j.jhep.2005.10.003]
81. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652 [PMID: 12939591 DOI: 10.1053/ jhep.2003.50364]
82. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID:21696307 DOI: 10.1056/NEJMoa1012912]
83. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355 [PMID: 14996676 DOI: 10.7326/0003-4819-140-5-200403020-00010]
84. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644 [PMID: 12939590 DOI: 10.1053/jhep.2003.50350]
85. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-1616 [PMID: 16697724 DOI: 10.1053/j.gastro.2006.02.023]
86. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, Drenth JP, Lonjon-Domanec I, DeMasi R, Picchio G, Beumont M, Marcellin P. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61: 1473-1480 [PMID: 22387529 DOI: 10.1136/gutjnl-2011-300749]
87. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687 [PMID: 11870384 DOI: 10.1053/jhep.2002.31773]
88. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262 [PMID: 16025497 DOI: 10.1002/hep.20793]
89. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713 [PMID:14643119 DOI: 10.1016/S0140-6736(03)14844-1]
90. Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012; 26: 2193-2199 [PMID:22781224 DOI: 10.1097/QAD.0b013e32835763a4]
91. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-S244 [PMID: 12407599 DOI: 10.1002/hep.1840360730]
92. Poordad F, Khungar V. Emerging therapeutic options in hepatitis C virus infection. Am J Manag Care 2011; 17 Suppl 4: S123-S130 [PMID: 21767068]
93. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917 [PMID:23675659]
94. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
95. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, Levy MT. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-1171 [PMID:20861806 DOI: 10.1097/TP.0b013e3181f92548]